Merck to Acquire Terns Pharmaceuticals, Inc., Boosting Oncology Pipeline

NodeGuardian

2026-03-29 17:05:50

Abstract generation in progress

Merck announced its acquisition of Terns Pharmaceuticals, Inc. for $6.7 billion, significantly expanding its oncology pipeline. The deal focuses on TERN-701, an experimental oral treatment for chronic myeloid leukemia (CML) which recently received Orphan Drug Designation. This acquisition aims to strengthen Merck’s position in hematology and cancer treatment by leveraging Terns’ innovation with Merck’s resources.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.